Belvedere Trading
COGT icon

Belvedere Trading’s Cogent Biosciences COGT Stock Holding History

Belvedere Trading’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,727
Closed -$98.6K – 941
2025
Q2 		$98.6K Buy
+13,727
New +$76.1K ﹤0.01% 520

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Belvedere Trading's COGT Position: Q3 2025 in Review

Belvedere Trading sold out of Cogent Biosciences (COGT) in Q3 2025, closing a stake of 13,727 shares — an estimated $98.6K sold.

Belvedere Trading first reported a position in COGT in Q2 2025 and held it in 1 quarter. The position peaked at $98.6K in Q2 2025. 195 funds tracked by Wall St. Rank hold COGT as of Q3 2025.

  • Belvedere Trading reported no remaining Cogent Biosciences position as of Q3 2025 after selling out during the quarter.
  • Belvedere Trading sold 13,727 Cogent Biosciences shares in Q3 2025, an estimated $98.6K.
  • Belvedere Trading first reported a position in Cogent Biosciences in Q2 2025 and held it in 1 quarter.
  • Belvedere Trading's Cogent Biosciences position peaked at $98.6K in Q2 2025.
  • 195 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2025.

Based on Belvedere Trading's 13F filing for Q3 2025, filed 27 Oct 2025.